StockTipsArenaBeta

BUY Onesource Specialty Pharma Limited — IDBI Capital

BUYOnesource Specialty Pharma Limited

byIDBI CapitalHorizon: 1–3 months29 May 2026via IDBI Capital Research Calls Telegram

Entry₹1,842Stated
Target₹2,000
Total upside +8.58% (call closed)
Stop loss₹1,755-4.72% risk
Exit₹1,7558 Jun 2026, 12:06 pm
Stop-loss hit-4.72%
Follow IDBI Capital for new calls(28% target hit, 117 closed calls)Get alertsWatch ONESOURCE for new buy/sell callsGet alertsSee 28 active Short-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 8 Sept, 4:15 pm IST
3 supporting1 neutral0 opposing
Supports the BUY call (3)

Onesource Specialty Pharma Limited announced its FY26 results with strong Q4 performance and reaffirmed its FY28 guidance in a press release.

NSE · Press Release·13 May · 4w ago

(opens in new tab)

1 advisor has an active long-term BUY call on this stock

Advisor consensus · adjacent horizon·13 Nov · 7mo ago

Neutral / worth noting (1)

Onesource Specialty Pharma Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.

NSE · Outcome of Board Meeting·13 May · 4w ago

(opens in new tab)
Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

StockTipsArena© 2026 · NSE equities only · Not investment advicePublic beta · data is auto-aggregated from public sources and may contain errors — verify before acting.